Related Post
Covid-19 a Mossad Psyop, aim was to use “vaccines” as bioweapons says Dr Bart Classen MD
Update May 2023
Baxter International said on Monday a private-equity group, which includes Warburg Pincus and Advent International, has agreed to buy its biopharma solutions unit for $4.25 billion.
Baxter International Inc.announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is operated by BioPharma Solutions (BPS), a business unit of Baxter that specializes in partnering with leading pharmaceutical and biotech companies on the development and contract manufacturing of drug product for parenteral (injectable) pharmaceuticals. Construction on the new manufacturing building is expected to begin in 2022 and be completed in 2024.
This strategic investment will expand the BPS manufacturing footprint and add state-of-the-art equipment designed to help products achieve stability and improved shelf life through lyophilization (freeze drying). Construction will also add an aseptic syringe filling line, enabling BPS to meet the growing demand for this delivery platform in both Europe and the United States. Pre-filled syringes can enhance efficiency and ease-of-use for clinicians and have potential to minimize microbial contamination and reduce medication dosing errors during medication preparation, which are key considerations for patient safety.
**My Note** A pre-filled syringe “vaccine” can be used to inject practically anything into a patient/victim since no one can examine the contents of a “pre filled vaccine”****
Baxter’s Halle/Westfalen, Germany site has more than 60 years of experience and is recognized as a world-class manufacturer of cytotoxic and highly potent drugs. Baxter’s Halle/Westfalen facility was previously expanded in 2015, which added capacity and new technologies to stay on the leading edge of manufacturing parenteral oncology therapies. In addition, Baxter’s Halle/Westfalen facility is engaged in multiple collaborations to provide sterile manufacturing services for COVID-19 vaccines.
According to reports, in 2009 “Professor Joseph Moshe had called into a live radio show by Dr. A.True Ott, broadcast on Republic Broadcasting claiming to be a microbiologist who wanted to supply evidence to a States Attorney regarding tainted H1N1 Swine flu vaccines being produced by Baxter BioPharma Solutions.
COVID-19 and Illegal US Bioweapons Activity, an Insider’s Revelations
He said that Baxter’s Ukrainian lab
was in fact producing a bioweapon disguised as a vaccine.
The FBI reportedly gave Mossad informant Joseph Moshe to
Israel, and he has not been heard of since
The original article was in a site called The Flu Case The site quotes more then one lawsuits against Baxter International and gives links to those lawsuits against Baxter in PDF form This is the present condition of the website
The website Biomedexperts.com (to which the above mentioned article links ) says Joseph Moshe is a plant disease expert with many publications to his name involving genetic manipulation of virii The present status of biomedexperts.com?
Following the Great War, the newly founded Czechoslovak state established a National Institute of Health to, among other things, develop and produce serums and vaccines. After World War II, a number of military facilities – particularly a laboratory of the Institute of Immunology and Microbiology of Jan Evangelista Purkyně Military Medical Academy in Těchonín in East Bohemia – became incorporated into the Soviet BW programme (Leitenberg, Zilinskas, and Kuhn Citation2012, 462–468). Yet, like elsewhere in the region, state funding declined immediate after 1990.
Two sources of rejuvenation emerged. The first was NATO membership, which upgraded Těchonín into CEE’s only military BSL-4 laboratory, with evidence of military-civilian collaborations in COVID-19-related biomedical research provided by publications in prominent journals such as Nature.Yet there is no evidence of spillovers from such research into the Czech biotechnological industry. Secondly, international biotech capital helped integrate the Czech biotech sector into high-value-added activities. After 1989, a plasma processing plant was built in Bohumil on a former vaccine production site of the National Institute of Health. The plant was privatised with American company Baxter and it produced flu vaccines using the advanced serum-free Vero cell technology for its European vaccine division. Baxter International has confirmed that vaccine shipments sent to subcontractors in Czech Republic, Slovenia and Germany were contaminated with live H5N1 avian flu viruses. The contaminated product, which Baxter calls “experimental virus material,” was a mix of H3N2 seasonal flu viruses and H5N1 viruses produced at the company’s research facility in Orth-Donau. The problem was discovered when ferrets inoculated with the experimental mix died. Baxter was notified on February 6, but has kept quiet about the details surrounding the mix-up, the Canadian Press reports.
In 2015, the Cyrus Poonawalla Group (which is the holding company that owns the Serum Institute of India, the world’s largest producer of vaccines that has partnered, among others, with AstraZenaca and Novavax to manufacture COVID-19 vaccines in India) purchased the facility from Baxter. In May 2020, the Bohumil facility was acquired by Novavax for USD 167 million to provide capabilities to produce a vaccine against COVID-19.
Both Serum Institute and Novavax produced nearly 2 billion of “Covid Vaccines”Serum Institute has also partnered with Oxford University-Astra Zeneca for manufacturing covid vaccine in India. Recently, the Drugs Controller General of India (DCGI) has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India.
Serum Institute of India has also reached an agreement with Novavax for the production of Novavax’s NVX-CoV2373 (Covovax) vaccine for India and other low and middle-income countries
In February 2009, the Austrian subsidiary of Baxter distributed 72 kilos of material contaminated with live virus vaccines for avian influenza to 16 laboratories in 4 countries and unleashed an investigation by the Austrian police. The Canadian Press (original article has disappeared from the internet) explained:
The contaminated product, which Baxter calls ‘experimental virus material’, was made at the Orth-Donau research facility in Austria. Baxter makes its flu vaccine – including a human H5N1 vaccine for which a licence is expected shortly – at a facility in the Czech Republic.
Baxter admits sending live avian flu viruses to subcontractor –Baxter admits contaminated seasonal flu product contained live bird flu virus
“People familiar with biosecurity rules are dismayed by evidence that human H3N2 and avian H5N1 viruses somehow co-mingled in the Orth-Donau facility. That is a dangerous practice that should not be allowed to happen, a number of experts insisted.”
Accidental release of a mixture of live H5N1 and H3N2 viruses could have resulted in dire consequences.”
While H5N1 doesn’t easily infect people, H3N2 viruses do. If someone exposed to a mixture of the two had been simultaneously infected with both strains, he or she could have been an incubator for a hybrid virus able to transmit easily to and among people.”That mixing process, called reassortment, is one of two ways pandemic viruses are created.
To sum up
- A Government owned Czech plant producing vaccines is bought out (privatized) by Baxter International in the 1990s
2)In February 2009, the Austrian subsidiary of Baxter distributed 72 kilos of material contaminated with live virus vaccines for avian influenza to 16 laboratories in 4 countries and unleashed an investigation by the Austrian police. Baxter International has confirmed that vaccine shipments sent to subcontractors in Czech Republic, Slovenia and Germany were contaminated with live H5N1 avian flu viruses. The contaminated product, which Baxter calls “experimental virus material,” was a mix of H3N2 seasonal flu viruses and H5N1 viruses produced at the company’s research facility in Orth-Donau.
3)Baxter International was sued for the”accidental” mixup
4)In 2014 Pfizer agreed to acquire Baxter International’s two vaccines commercially marketed outside the U.S., and Baxter’s facility in Orth, Austria, where the vaccines are manufactured.for $635 million,
5)In 2014/15 after its sale to Nanotheraputics Baxter international completely exited the Vaccine market
6) In 2017 Nanotherapeutics Bohumil s.r.o., a wholly owned subsidiary of Nanotherapeutics, Inc., and Cyrus Poonawalla Group announced that the final transfer of Nanotherapeutics Bohumil s.r.o.’s vaccine production enterprise located in Bohumil, Czech Republic to Praha Vaccines a.s. Nanotherapeutics was previously acquired from Baxter International in 2015.Poonwalla went on to manufacture 2 billion Covid vector virus “vaccines” with AstraZenecas technology In 2016 Nanotherapeutics, Inc’s appointed former Gates Foundation employee Peter Khoury as its CEO
7)Serum Institute of India has also reached an agreement with Novavax for the production of Novavax’s NVX-CoV2373 (Covovax) vaccine for India and other low and middle-income countries
8)Baxter International Inc said a private-equity group, which includes Warburg Pincus and Advent International, buy its biopharma solutions unit for $4.25 billion.Bio-pharma is the application of living organisms or extractions, by-products or components of living organisms, to prevent, relieve, or treat diseases.
New World Order Broadcast Corp 